Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47

Benzinga · 1d ago
Wells Fargo analyst Derek Archila maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $45 to $47.